A phase 3 randomized clinical trial assessed the safety and efficacy of once-daily roflumilast foam, 0.3%, for treating psoriasis involving the scalp and body. Patients experienced significant scalp itch relief within 8 weeks, with some showing improvement as early as 24 hours after the first application, leading to enhanced adherence to treatment and favorable patient-reported outcomes.

Source: JAMA Dermatology